Goldman Sachs’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $346K | Sell |
74,554
-110,183
| -60% | -$286K | ﹤0.01% | 5934 |
|
|
2026
Q1 | $515K | Sell |
184,737
-122,492
| -40% | -$373K | ﹤0.01% | 5578 |
|
|
2025
Q4 | $1.28M | Buy |
307,229
+285,215
| +1,296% | +$1.5M | ﹤0.01% | 4938 |
|
|
2025
Q3 | $93.2K | Sell |
22,014
-4,255
| -16% | -$16K | ﹤0.01% | 6092 |
|
|
2025
Q2 | $55.4K | Buy |
26,269
+15,570
| +146% | +$23.3K | ﹤0.01% | 5899 |
|
|
2025
Q1 | $13.1K | Sell |
10,699
-36,822
| -77% | -$51.7K | ﹤0.01% | 5962 |
|
|
2024
Q4 | $61.3K | Buy |
47,521
+14,489
| +44% | +$34.7K | ﹤0.01% | 5832 |
|
|
2024
Q3 | $90.8K | Buy |
33,032
+10,469
| +46% | +$25.7K | ﹤0.01% | 5578 |
|
|
2024
Q2 | $51K | Buy |
+22,563
| New | +$68.5K | ﹤0.01% | 5467 |
|
|
2022
Q3 | – | Sell |
-18,419
| Closed | -$24K | – | 6369 |
|
|
2022
Q2 | $24K | Buy |
18,419
+7,659
| +71% | +$11K | ﹤0.01% | 6145 |
|
|
2022
Q1 | $17K | Sell |
10,760
-531
| -5% | -$1.03K | ﹤0.01% | 6432 |
|
|
2021
Q4 | $23K | Sell |
11,291
-3,426
| -23% | -$9.78K | ﹤0.01% | 6356 |
|
|
2021
Q3 | $57K | Sell |
14,717
-3,458
| -19% | -$11.7K | ﹤0.01% | 6018 |
|
|
2021
Q2 | $58K | Sell |
18,175
-2,637
| -13% | -$9.38K | ﹤0.01% | 6053 |
|
|
2021
Q1 | $45K | Sell |
20,812
-2,349
| -10% | -$5.26K | ﹤0.01% | 5952 |
|
|
2020
Q4 | $52K | Buy |
23,161
+2,507
| +12% | +$6.58K | ﹤0.01% | 5378 |
|
|
2020
Q3 | $55K | Sell |
20,654
-140
| -0.7% | -$392 | ﹤0.01% | 5178 |
|
|
2020
Q2 | $64K | Buy |
20,794
+4,119
| +25% | +$10.4K | ﹤0.01% | 5047 |
|
|
2020
Q1 | $33K | Sell |
16,675
-15,401
| -48% | -$37.5K | ﹤0.01% | 5092 |
|
|
2019
Q4 | $92K | Sell |
32,076
-9,516
| -23% | -$33.1K | ﹤0.01% | 5052 |
|
|
2019
Q3 | $152K | Buy |
+41,592
| New | +$150K | ﹤0.01% | 4895 |
|
|
2019
Q2 | – | Sell |
-174,391
| Closed | -$891K | – | 5205 |
|
|
2019
Q1 | $891K | Buy |
174,391
+160,323
| +1,140% | +$770K | ﹤0.01% | 4129 |
|
|
2018
Q4 | $48K | Sell |
14,068
-1,888
| -12% | -$9.02K | ﹤0.01% | 5096 |
|
|
2018
Q3 | $96K | Buy |
+15,956
| New | +$87.8K | ﹤0.01% | 5152 |
|
|
2018
Q1 | – | Sell |
-12,528
| Closed | -$42K | – | 6067 |
|
|
2017
Q4 | $42K | Sell |
12,528
-1,521
| -11% | -$3.85K | ﹤0.01% | 5971 |
|
|
2017
Q3 | $30K | Sell |
14,049
-3,055
| -18% | -$6.05K | ﹤0.01% | 6365 |
|
|
2017
Q2 | $42K | Sell |
17,104
-267
| -2% | -$711 | ﹤0.01% | 6396 |
|
|
2017
Q1 | $40K | Buy |
17,371
+2,026
| +13% | +$3.05K | ﹤0.01% | 6351 |
|
|
2016
Q4 | $15K | Buy |
15,345
+174
| +1% | +$155 | ﹤0.01% | 6705 |
|
|
2016
Q3 | $17K | Sell |
15,171
-67
| -0.4% | -$119 | ﹤0.01% | 6789 |
|
|
2016
Q2 | $22K | Sell |
15,238
-1,043
| -6% | -$1.53K | ﹤0.01% | 6689 |
|
|
2016
Q1 | $23K | Sell |
16,281
-7,664
| -32% | -$10.3K | ﹤0.01% | 6707 |
|
|
2015
Q4 | $39K | Sell |
23,945
-18,987
| -44% | -$43.5K | ﹤0.01% | 6651 |
|
|
2015
Q3 | $100K | Sell |
42,932
-2,580
| -6% | -$6.08K | ﹤0.01% | 6481 |
|
|
2015
Q2 | $124K | Buy |
45,512
+26,476
| +139% | +$79.8K | ﹤0.01% | 6494 |
|
|
2015
Q1 | $64K | Buy |
19,036
+4,996
| +36% | +$17.8K | ﹤0.01% | 6617 |
|
|
2014
Q4 | $49K | Buy |
14,040
+2,999
| +27% | +$13.3K | ﹤0.01% | 6817 |
|
|
2014
Q3 | $56K | Sell |
11,041
-30,869
| -74% | -$240K | ﹤0.01% | 6784 |
|
|
2014
Q2 | $579K | Buy |
41,910
+36,766
| +715% | +$458K | ﹤0.01% | 5178 |
|
|
2014
Q1 | $79K | Buy |
+5,144
| New | +$73.3K | ﹤0.01% | 6465 |
|
Other funds holding GALT
WANY
Goldman Sachs's GALT Position: Q2 2026 in Review
Goldman Sachs reduced its Galectin Therapeutics (GALT) stake by 60% in Q2 2026, selling an estimated $286K and leaving 74,554 shares worth $346K. The position accounts for ﹤0.01% of the portfolio, ranked #5934.
Goldman Sachs first reported a position in GALT in Q1 2014 and has held it in 40 quarters since. The position peaked at $1.28M in Q4 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.
- Goldman Sachs held 74,554 shares of Galectin Therapeutics worth $346K as of Q2 2026.
- Goldman Sachs sold 110,183 Galectin Therapeutics shares in Q2 2026, an estimated $286K.
- Galectin Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5934 holding.
- Goldman Sachs first reported a position in Galectin Therapeutics in Q1 2014 and has held it in 40 quarters since.
- Goldman Sachs's Galectin Therapeutics position peaked at $1.28M in Q4 2025.
- 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.